Regulatory Routine +

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 08:00 OPTI · 6.5 Optimi Health Corp.

Executive Summary

Optimi Health Corp. secured naturally derived ibogaine in hydrochloride and freebase forms from two sources.
Finished drug product development for 50mg and 100mg encapsulated formats will commence this summer at its Canadian GMP facility.
The development program covers SOPs, manufacturing validation, and analytical testing for encapsulation, bottling, labeling, and packaging.
The update follows a U.S. Executive Order (April 18, 2026) prioritizing ibogaine for accelerated FDA review and expanded patient access, with federal funding directed to match state investments.
Ibogaine is not a controlled substance in Canada (regulated under the Food and Drugs Act), contrasting with its Schedule I status in the United States.
Clinical indications under investigation include PTSD, opioid use disorder, and traumatic brain injury (TBI).
The company's Canadian GMP facility also manufactures psilocybin and MDMA for clinical research and regulated patient access.
A progress update will be provided upon completion of the in-house development program.

Material Impact

The announcement represents an operational milestone rather than a financial inflection point. It confirms execution on the "Ibogaine Initiative" launched in April 2026.
No revenue, pricing, or contract values are disclosed. The company is in the pre-clinical/development phase for this new product line.
The U.S. Executive Order provides a favorable policy backdrop, but it is non-binding and does not guarantee FDA approval or reimbursement pathways. Ibogaine remains Schedule I in the U.S., meaning commercial sales are still years away.
The news does not alter the company's immediate cash burn or near-term revenue trajectory. It is a strategic positioning move to capture future demand in a nascent market.

OPTI · Price

Company Overview

Optimi Health Corp. is a vertically integrated, Health Canada-licensed GMP manufacturer specializing in controlled psychedelic substances.
Core products include MDMA (for PTSD) and naturally derived psilocybin (for treatment-resistant depression), manufactured at two 10,000 sq ft facilities in British Columbia.
The company has a commercial footprint in Australia under the Therapeutic Goods Administration's Authorized Prescriber Scheme, with reimbursement from public and private payers.
It also supplies GMP-grade finished drug products and APIs for clinical research globally, including trials in Israel, the U.S., and Europe.
The company recently uplisted to the Nasdaq Capital Market (ticker: OPTH) following a $15M USD public offering and a 1-for-30 reverse stock consolidation.

More from Optimi Health Corp.